Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

China · Delayed Price · Currency is CNY

17.84

+0.39 (2.23%)

At close: Aug 4, 2026

Jiangsu CoWin Biotech Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	209.51	193.52	125.88	171.34	521.6	338.46
Revenue Growth	49.57%	53.74%	-26.53%	-67.15%	54.11%	45.13%
Gross Profit	89.43	83.4	63.09	103.79	360.91	243.44
Operating Income	-121.11	-132.59	-190.64	-139.35	176.36	130.93
Net Income	-100.02	-107.41	-157.21	-84.41	159.26	125.85
Earnings Per Share	-0.91	-0.98	-1.41	-0.75	1.72	1.49
EPS Growth	-	-	-	-	14.97%	-3.24%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Selling goods	114.94
Services	78.48
Total	193.41

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	724.54	888.22	733.05	983.64	1,434	361.25
Total Debt	10.33	14.45	27.84	32.95	40.77	39.99
Net Cash (Debt)	714.21	873.77	705.21	950.68	1,393	321.25
Net Cash Growth	14.96%	23.90%	-25.82%	-31.77%	333.73%	-6.07%
Net Cash Per Share	6.50	7.97	6.32	8.45	15.00	3.81

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-74.66	-58.99	-113.26	-11.72	107.37	144.5
Capital Expenditures	-24.83	-34.82	-48.41	-159.22	-100.38	-124.39
Free Cash Flow	-99.49	-93.82	-161.67	-170.94	6.99	20.11
Free Cash Flow Growth	-	-	-	-	-65.25%	-78.93%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	42.69%	43.09%	50.12%	60.58%	69.19%	71.92%
Operating Margin	-57.81%	-68.52%	-151.45%	-81.33%	33.81%	38.69%
Pretax Margin	-46.77%	-55.06%	-130.85%	-54.27%	37.46%	42.70%
Profit Margin	-47.74%	-55.51%	-124.89%	-49.26%	30.53%	37.18%
FCF Margin	-47.49%	-48.48%	-128.44%	-99.77%	1.34%	5.94%

Dividends

Fiscal Year	FY 2022
Period Ending	Dec '22 Dec 31, 2022
Dividend Per Share	0.433
Dividend Per Share Growth	-
Dividend Yield	1.49%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	20.81	-
Forward PE	-	21.80	21.80	21.80	-	-
P/FCF Ratio	-	-	-	-	474.27	-
PS Ratio	9.16	13.54	25.26	20.01	6.35	-